What Is Retatrutide (Reta)?

Benefits, Risks, and Clinical Trial Results

Retatrutide (often called "Reta" online) is an experimental weight loss and metabolic medication developed by Eli Lilly and Company. It's been ramping up significant attention because clinical trials suggest it may produce some of the best non-surgical weight loss results ever reported with a medication.

Unlike other GLP-1 medications, retatrutide works by targeting three hormone receptors at the same time, which may explain its powerful effects on appetite, blood sugar regulation, and fat metabolism.

As of May 2026, retatrutide is not yet FDA-approved, though multiple Phase 3 clinical trials are ongoing.

What Is Retatrutide Actually?

Retatrutide is a once-weekly injectable medication that acts as a:

• GLP-1 receptor agonist
• GIP receptor agonist
• Glucagon receptor agonist

This combination makes it a triple hormone receptor agonist, differentiating it from medications like Ozempic (GLP-1 only) or Zepbound/Mounjaro (GLP-1 + GIP).

Researchers believe the third glucagon component may help increase energy spending and fat burning while GLP-1 and GIP reduce hunger and improve insulin sensitivity.

How Does Retatrutide Work?

Retatrutide appears to support weight loss and metabolic health through several mechanisms:

• Reducing appetite and food cravings (decreased food noise)
• Slowing stomach emptying
• Improving insulin response
• Increasing calorie burn
• Enhancing fat breakdown

Researchers from the New England Journal of Medicine reported that retatrutide produced weight loss levels comparable to bariatric surgery outcomes in some patients.

Retatrutide vs Semaglutide vs Tirzepatide: Key Differences for Weight Loss

If you're comparing retatrutide vs semaglutide vs tirzepatide, the main difference is how many hormone receptors each medication targets, and how much weight loss they may encourage:

Semaglutide (main ingredient in Ozempic and Wegovy) targets GLP-1 hormones only and has shown average weight loss of around 15% of their starting body weight in clinical trials.

Tirzepatide (main ingredient in Mounjaro and Zepbound) targets GLP-1 + GIP, leading to greater average weight loss of approximately 20–22%.

Retatrutide is a newer triple-agonist weight loss drug that targets GLP-1 + GIP + glucagon receptors, potentially increasing both appetite suppression and fat burning. Early Phase 3 clinical trial data suggest retatrutide may produce the greatest results so far, with participants losing up to 28% of body weight. However, retatrutide is still in trials and has not yet received FDA approval.

Benefits of Retatrutide

Significant Weight Loss

The largest Phase 2 trial published in the New England Journal of Medicine found substantial weight reduction among adults with obesity.

Participants taking the highest dose achieved:

• Average weight loss approaching 24% at 48 weeks
• Nearly half lost 25% or more of body weight
• About one-quarter lost 30% or more

More recent Phase 3 TRIUMPH-1 data released in 2026 showed participants lost an average of 28.3% of body weight after 80 weeks on the highest dose.

Improved Blood Sugar Control

Retatrutide has also shown strong results for type 2 diabetes management.

According to Phase 3 trial data released by Eli Lilly Investor Relations, retatrutide reduced HbA1c levels by approximately 1.7% to 2.0% after 40 weeks.

Researchers believe the drug's multi-hormone approach may improve insulin sensitivity more effectively than earlier GLP-1 medications.

Potential Cardiovascular and Metabolic Benefits

Clinical trials have also shown improvements in:

• Blood pressure
• Waist circumference
• Cholesterol markers
• Liver fat levels
• Inflammatory markers

These changes could potentially reduce long-term risks associated with obesity and metabolic syndrome, although long-term cardiovascular outcome studies are still ongoing.

Possible Benefits for Obesity-Related Conditions

Retatrutide is currently being studied for several obesity-related conditions, including:

• Obstructive sleep apnea
• Osteoarthritis
• Type 2 diabetes
• Cardiometabolic disease

The ongoing TRIUMPH clinical program is evaluating whether substantial weight reduction can improve these chronic conditions.

Risks and Side Effects of Retatrutide

Like other popular weight loss drugs, retatrutide can cause side effects, especially during dose increases. The most common retatrutide side effects reported in clinical trials include nausea, vomiting, diarrhea, constipation, stomach pain, and appetite loss. A 2025 systematic review published through PubMed Central found gastrointestinal symptoms increased with higher doses of retatrutide.

Researchers are still studying the long-term safety of retatrutide, including possible muscle loss and cardiovascular risks, because the drug is still investigational and not yet FDA-approved. This remains an active area of obesity medicine research.

Medical experts also warn people to avoid buying "research peptide" versions of retatrutide online, since counterfeit products may contain harmful or contaminated ingredients. Retatrutide is not yet FDA-approved, so access is generally limited to clinical trials.

Is Retatrutide FDA Approved?

No. Retatrutide is still considered an investigational medication in the United States as of May 2026.

However, Eli Lilly has reported positive Phase 3 trial results and is expected to seek FDA approval between late 2026 to early 2027.

Who Might Benefit From Retatrutide?

Based on current clinical research, retatrutide may eventually become an option for adults with:

• Obesity (BMI ≥30)
• Overweight with metabolic complications
• Type 2 diabetes
• Sleep apnea related to obesity
• Weight-related osteoarthritis

Treatment decisions would ultimately depend on FDA approval and physician evaluation.

Book your optimization consult to see if any of these drugs are right for you.

Book Consult

Bloom Metabolics evaluates your health as a whole to help you feel and function at your best. Physician-led protocols are tailored to your unique health needs based on comprehensive lab results.

The Forefront of Weight Management Medicine

Retatrutide represents one of the most promising developments in obesity medicine in recent years. Early clinical trials suggest it may outperform earlier GLP-1 medications in terms of weight loss and metabolic improvement.

At the same time, the medication remains experimental. Gastrointestinal side effects are common, long-term safety data are still developing, and experts strongly caution against obtaining unregulated versions online.

As more Phase 3 trial data emerge, retatrutide may become a major advancement in weight management and metabolic disease.

Stay in the loop with the newest developments in weight loss medication by subscribing to our newsletter.

Sources

• New England Journal of Medicine – Retatrutide Phase 2 Trial (Jastreboff et al., 2023)
• Eli Lilly Investor Relations – Retatrutide Press Releases
• ClinicalTrials.gov – Retatrutide Studies
• PubMed – Retatrutide Safety Literature
• Reuters – Eli Lilly Retatrutide Coverage
• TRIUMPH Clinical Program – Retatrutide Phase 3 Trials